Last edition
News about "Barzolvolimab"
Celldex Reports Sustained Angioedema Improvement with Barzolvolimab in CSU
Celldex presented long-term data showing barzolvolimab delivered sustained off-treatment improvement in angioedema among patients with Chronic Spontaneous Urticaria (CSU).Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU.
Barzolvolimab | 16/06/2026 | By News Bureau | 101
Barzolvolimab Shows Sustained, Off-Treatment Benefits in Chronic Spontaneous Urticaria at AAAAI 2026
Phase II data presented at AAAAI 2026 show barzolvolimab achieved rapid, durable complete responses in chronic spontaneous urticaria, with sustained disease control observed months after treatment discontinuation.
Barzolvolimab | 12/02/2026 | By News Bureau | 301
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy